Anidulafungin (INN) (sold under the brand name Eraxis among others, is a semisynthetic echinocandin used as an antifungal medication. It may also have application in treating invasive Aspergillus infection when used in combination with voriconazole. It is a member of the class of antifungal drugs known as the echinocandins; its mechanism of action is by inhibition of (1→3)-β-D-glucan synthase, an enzyme important to the synthesis of the fungal cell wall.
via PubMed
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 457130635 | IUPAC_name = N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2R)-1,2-Dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.09,13]heptacosan-18-yl]- 4-{4-[4-(pentyloxy)phenyl]phenyl}benzamide | image = Anidulafungin structure.svg | image_class = skin-invert-image | width = 300 | alt =
| pronounce = | tradename = Eraxis, others | Drugs.com = | DailyMedID = Anidulafungin | routes_of_administration = Intravenous
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).